Elthera AG

Elthera AG is developing antibodies against the novel target L1CAM, an adhesion molecule whose expression is strongly correlated with an aggressive tumor phenotype and poor prognosis in various types of cancer. Inhibition of L1CAM targets many mechanisms of tumor progression such as resistance to chemotherapy, escape from immunological control, formation of new blood vessels, tumor growth and metastases formation. By combining targeted anti-L1CAM therapy with companion diagnostics, Elthera will provide personalized treatment for patients with aggressive malignancies. The therapies are using two approaches for an enhanced anti-cancer effect by distinct mechanisms of action: a T cell engaging anti-L1CAMxCD3 bispecific antibody and an antibody-drug conjugate for targeted tumor cell killing